PAK1 Expression Determines Poor Prognosis and Immune Evasion in Metastatic Renal Cell Carcinoma Patients.
Yang Qu,Zhiyuan Lin,Yu Qi,Yangyang Qi,Yifan Chen,Quan Zhou,Han Zeng,Zheng Liu,Zewei Wang,Jiajun Wang,Yuan Chang,Qi Bai,Yu Xia,Yiwei Wang,Yu Zhu,Le Xu,Lingli Chen,Peipei Zhang,Weijuan Zhang,Bo Dai,Li Liu,Jiejie Xu,Jianming Guo
DOI: https://doi.org/10.1016/j.urolonc.2019.10.010
IF: 2.954
2019-01-01
Urologic Oncology Seminars and Original Investigations
Abstract:Background: Previous studies have shown the prognostic value of PAK1 expression in different tumor patients, including nonmetastatic renal cell carcinoma. In this study, we explored the prognostic and drug predictive value of PAK1 expression in metastatic renal cell carcinoma (mRCC) patients treated with tyrosine kinase inhibitors (TKIs). Materials and Methods: We retrospectively enrolled 138 mRCC patients treated with TKIs from a single institution from 2005 to 2014. Analyses were based on 111 patients who met our inclusion criteria. The validation set enrolled 538 RCC patients from The Cancer Genome Atlas Kidney Renal Clear Cell Carcinoma cohort (TCGA KIRC) between 1998 and 2013 in North America. PAK1 expression was assessed by immunohistochemistry (IHC) on tissue microarrays. Results: High PAK1 expression was associated with short overall survival (OS) (P < 0.001) and progression-free survival (PFS) (P = 0.008). Multivariate analyses further indicated that PAK1 expression was an independent prognostic factor for OS (hazard ratio 3.301 [95% confidence interval 2.579-10.899], P < 0.001) and PFS (hazard ratio 3.108 [95% confidence interval 1.795-5.381], P < 0.001). Subgroup analyses suggested that PAK1 was more significant in patients with the intermediate risk group of Heng risk criteria (OS, P = 0.004). Of note, patients treated with Sunitinib showed improved outcome in the low PAK1 subgroup (OS, P = 0.002; PFS, P = 0.013). Finally, relationship was found between PAK1 expression and natural killer cell-mediated cytotoxicity according to gene profile investigation. Conclusions: High PAK1 expression predicted dismal prognosis in mRCC patients treated with TKIs. Besides, PAK1 was a potential predictor for TKIs treatments. (C) 2019 Elsevier Inc. All rights reserved.